TICKERNERD
Menu
LLYLLYHealthcare · Drug Manufacturers - General

LLY Stock Forecast: Eli Lilly & Co. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$1,288
+0.50% on the day

The 31 Wall Street analysts covering Eli Lilly & Co. hold a median 12-month price target of $1,400 — +8.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 27 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.1T
Ticker Nerd rank
81/ 100
Median analyst target
$1,400
Analysts covering
31
Revenue$23.0B+47.7% y/y
Operating income$12.5B
Net income$7.1B
Free cash flow$4.5B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.4%
1M
+8.7%
YTD
+20.5%
1Y
+58.1%
From 52W high
−1.4%
From 52W low
+59.4%
$808
$1,307
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LLY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Eli Lilly & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026
81/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Quality
98
Value
96
Momentum
94
Growth
87
Revisions
59
Issuance
40
Accruals
22
Size
0

Volatility (99): The share price has been relatively steady.

Accruals (22): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LLY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LLY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$800$1,000$1,200$1,400$1,600Jan 26Apr 26Jul 26Oct 26LLYHigh $1,600Median $1,400Low $930

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says31 analysts
26 Buy3 Hold2 Sell
Low $930Median $1,400High $1,600

The green dot is the last close — the median target sits +8.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
21 Oct 2026Leerink PartnersMaintainsOutperform$1,309 → $1,316
12 Oct 2026RBC CapitalReiteratesOutperform$1,500
12 Oct 2026RBC CapitalReiteratesOutperform—
8 Oct 2026Cantor FitzgeraldMaintainsOverweight—
8 Oct 2026Cantor FitzgeraldMaintainsOverweight$1,410 → $1,440
7 Oct 2026Morgan StanleyMaintainsOverweight$1,419 → $1,430
7 Oct 2026Morgan StanleyMaintainsOverweight—
28 Sept 2026JP MorganMaintainsOverweight—
28 Sept 2026JP MorganMaintainsOverweight$1,400 → $1,500
22 Sept 2026TD CowenReiteratesBuy$1,250
22 Sept 2026TD CowenReiteratesBuy—
18 Sept 2026GuggenheimMaintainsBuy—
18 Sept 2026GuggenheimMaintainsBuy$1,273 → $1,284
10 Sept 2026HSBCMaintainsReduce—
10 Sept 2026HSBCMaintainsReduce$850 → $940
7 Aug 2026Truist SecuritiesMaintainsBuy—
7 Aug 2026Truist SecuritiesMaintainsBuy$1,370 → $1,376
6 Aug 2026Cantor FitzgeraldMaintainsOverweight$1,350 → $1,410
6 Aug 2026Cantor FitzgeraldMaintainsOverweight—
6 Aug 2026Wells FargoMaintainsOverweight$1,280 → $1,330

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

LLY appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LLY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Eli Lilly & Co. returned +58.1% against +13.6% for the S&P 500, dividends included.

LLY vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Jan 26Apr 26Jul 26Oct 26LLYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LLY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.5%
Analysts raising
5
Analysts cutting
8
Fundamentals

Eli Lilly & Co. (LLY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
43.2×

Cheaper than 17% of US stocks

Price / sales
14.4×

Cheaper than 10% of US stocks

Price / book
33.9×

Cheaper than 3% of US stocks

EV / EBITDA
28.5×

Cheaper than 9% of US stocks

Growth & margins
Revenue growth (YoY)
47.7%

Higher than 85% of US stocks

Earnings growth (YoY)
25.3%

Higher than 63% of US stocks

Gross margin
85.8%

Higher than 94% of US stocks

Operating margin
54.2%

Higher than 97% of US stocks

Net margin
33.5%

Higher than 91% of US stocks

Returns & dividend
Return on equity
102.3%

Higher than 96% of US stocks

Return on assets
20.4%

Higher than 99% of US stocks

Dividend yield
0.5%

Higher than 66% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Eli Lilly & Co. (LLY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Eli Lilly & Co. has a market value of $1.1T and an enterprise value of $1.2T.

  • Revenue in the twelve months to 30 June 2026: $79.7B. The latest quarter grew 47.7% year on year.

  • Net income over the same four quarters: $26.7B, a 33.5% net margin.

  • Diluted earnings per share, trailing twelve months: $29.80.

  • Free cash flow in the twelve months to 30 June 2026: $13.6B.

  • Eli Lilly & Co. spent $6.2B on share buybacks and $5.8B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 891.5M.

  • Trailing P/E: 43.2×; forward P/E: 27.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.54%, paying out 22% of earnings.

  • Eli Lilly & Co. employs 50,000 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

LLY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
LLYEli Lilly & Co.$1.1T81
JNJJohnson & Johnson$647.6B84
ABBVAbbVie, Inc.$506.0B94
MRKMerck & Co., Inc.$352.0B79
AMGNAmgen, Inc.$241.5B94
GILDGilead Sciences, Inc.$197.5B98
PFEPfizer Inc.$169.4B81

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Eli Lilly & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LLY news & analysis

16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage

24/7 Wall Street · 28 Oct 2026negative

The article reports that 16% of employers are considering cutting coverage for GLP-1 weight-loss drugs, as employers reconsider who pays for the medications. It says the potential effects differ for Eli Lilly and Novo Nordisk ahead of earnings week.

Why it matters — A Lilly watcher may want to follow employer coverage decisions because the article highlights them as a potential factor affecting the company differently from Novo Nordisk.

How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3?

Zacks Investment Research · 28 Oct 2026positive

Eli Lilly is expanding beyond GLP-1 drugs, with neuroscience and immunology therapies—including Kisunla, Taltz and newer drugs—in focus ahead of its Q3 results.

Why it matters — LLY watchers may track how these therapy areas contribute to the company’s growth beyond GLP-1 drugs.

Ghabour: Fed "Biggest Risk to Bull Market;" Bullish on MSFT, CRWD, LLY

Schwab Network · 28 Oct 2026positive

Eddie Ghabour identified the Federal Reserve as the biggest risk to the current bull market, saying he believes the FOMC has tightened enough and that a likely December rate increase could weigh on equity investors. The headline lists LLY among the stocks on which he is bullish.

Why it matters — The item includes a bullish view on Eli Lilly, while also highlighting concern about the potential effect of Fed policy on equity investors.

Lilly's Reta Trounces Novo Powerhouse In Head-To-Head Test

Investors Business Daily · 28 Oct 2026positive

Eli Lilly said its next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study.

Why it matters — The reported study result concerns a potential next-generation weight-loss drug from Lilly.

3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead

24/7 Wall Street · 28 Oct 2026negative

The article highlights three pharma earnings concerns: Eli Lilly’s EPS estimate fell by a third in 30 days, Merck faces a difficult comparison, and Gilead is using cash quickly.

Why it matters — LLY watchers may note the reported sharp recent decline in the company’s EPS estimate ahead of its earnings report.

FAQ

Frequently asked questions about LLY stock

What is the LLY stock price forecast for 2026-2027?

The 31 Wall Street analysts covering Eli Lilly & Co. have a median 12-month price target of $1,400, with estimates ranging from $930 to $1,600. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LLY stock a buy right now?

Of the 31 analysts covering Eli Lilly & Co., 26 rate it a Buy, 3 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Eli Lilly & Co. 81 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LLY?

As at 27 Oct 2026, Eli Lilly & Co. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will LLY stock go up?

No one can know that. What the data says: the median 12-month target from 31 analysts implies +8.7% from the last close, and Ticker Nerd's factor model ranks Eli Lilly & Co. 81 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LLY stock forecast for 2030?

No analyst covering Eli Lilly & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LLY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $930 to $1,600 over the next 12 months.

How has LLY stock performed over the past year?

Eli Lilly & Co. returned +58.1% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Eli Lilly & Co. do?

Eli Lilly and Company is a global medicine company focused on discovering, developing, manufacturing, and marketing human pharmaceutical products. Eli Lilly and Company operates across major therapeutic areas including diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular care, serving patients, healthcare providers, and health systems worldwide.

What is the latest news on LLY?

The most recent item we track (24/7 Wall Street, 28 Oct 2026): "16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage". The article reports that 16% of employers are considering cutting coverage for GLP-1 weight-loss drugs, as employers reconsider who pays for the medications. It says the potential effects differ for Eli Lilly and Novo Nordisk ahead of earnings week.

Company

About Eli Lilly & Co.

Eli Lilly and Company is a global medicine company focused on discovering, developing, manufacturing, and marketing human pharmaceutical products. Eli Lilly and Company operates across major therapeutic areas including diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular care, serving patients, healthcare providers, and health systems worldwide. Its current portfolio includes widely used treatments for chronic metabolic conditions as well as therapies for cancer and immune-related diseases, supported by ongoing commercial operations and regulated manufacturing capacity in the United States, Europe, and Asia. The company also advances diagnostics and specialty medicines that address complex medical needs in hospital, outpatient, and community settings. Eli Lilly and Company plays a significant role in the pharmaceutical market through its broad product lineup, large-scale distribution network, and focus on prescription medicines that are used in everyday clinical practice.

CEO Mr. David A. Ricks · 50,000 employees · United States · https://www.lilly.com